Theralase Technologies Inc
XTSX:TLT

Watchlist Manager
Theralase Technologies Inc Logo
Theralase Technologies Inc
XTSX:TLT
Watchlist
Price: 0.3 CAD 3.45% Market Closed
Market Cap: 72.8m CAD
Have any thoughts about
Theralase Technologies Inc?
Write Note

Theralase Technologies Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Theralase Technologies Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Theralase Technologies Inc
XTSX:TLT
Interest Income Expense
CA$24.3k
CAGR 3-Years
21%
CAGR 5-Years
120%
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Interest Income Expense
$327k
CAGR 3-Years
N/A
CAGR 5-Years
-47%
CAGR 10-Years
N/A
Profound Medical Corp
TSX:PRN
Interest Income Expense
$2.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Interest Income Expense
CA$400k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanalysis Scientific Corp
XTSX:NSCI
Interest Income Expense
-CA$3.8m
CAGR 3-Years
N/A
CAGR 5-Years
-97%
CAGR 10-Years
N/A
MedMira Inc
XTSX:MIR
Interest Income Expense
-CA$1.1m
CAGR 3-Years
-16%
CAGR 5-Years
-5%
CAGR 10-Years
-3%
No Stocks Found

Theralase Technologies Inc
Glance View

Market Cap
71.8m CAD
Industry
Health Care

Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.

TLT Intrinsic Value
0.96 CAD
Undervaluation 69%
Intrinsic Value
Price

See Also

What is Theralase Technologies Inc's Interest Income Expense?
Interest Income Expense
24.3k CAD

Based on the financial report for Jun 30, 2024, Theralase Technologies Inc's Interest Income Expense amounts to 24.3k CAD.

What is Theralase Technologies Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
120%

The average annual Interest Income Expense growth rates for Theralase Technologies Inc have been 21% over the past three years , 120% over the past five years .

Back to Top